CN210373855: The utility model provides an air purifier relates to air purification technical field, and this air purifier includes: the liquid storage tank is used for storing decomposition liquid, the liquid storage tank is connected with the upper end of the filtering structure, and a plurality of first leakage holes are formed in the connection position of the liquid storage tank and the filtering structure; the air purifier comprises an air guide channel, and the filtering structure is positioned in the air guide channel and used for filtering air passing through the air guide channel. The air purifier can comprehensively finish sterilization, deodorization, formaldehyde removal and the like, and the decomposition liquid can adsorb smoke floating dust, haze and suspended particles in the air, and is matched with the filtering structure to be beneficial to comprehensively removing particle pollutants in the air; and compared with the traditional filter element, the filter element has the advantages of low price of filtrate, low material consumption and low use cost.
The genic construct comprises: (i) at least a first gene (FUCCIplex) for or a partial fragment of a gene for at least a first expression product the quantity of which in a cell varies in a cell cycle-dependent manner; and at least one of: (ii) at least a second gene for or a partial fragment of a gene for at least a second expression product the quantity of which in a cell varies in a cell structure-dependent manner; (iii) at least a third gene for or a partial fragment of a gene for at least a third expression product the quantity of which in a cell varies in a cell function- dependent manner.
The present invention relates to a method for the identification of the whole nucleotide sequence of the variable region of the heavy and or light chains of immunoglobulins in a biological sample and the quantification of their relative frequency. The invention is particularly used for the identification of monoclonal heavy and light chains, i.e. tumours, in biological samples from patients suffering from a monoclonal gammapathy.
A surgical training device (100), in particular for simulating a pyeloplasty operation, more in particular for simulating a pyeloplasty operation in paediatric age, comprising a first structure (10) adapted to simulate at least one renal parenchyma (11), a main renal artery (12) and an inferior polar artery (13), and a second structure (20) adapted to simulate a renal pelvis (21), a pyelo-ureteral junction (22) and at least partially a ureter (23), wherein the second structure (20) comprises a ureteral defect adapted to undergo a surgical training procedure. The first structure (10) and the second structure (20) are mechanically coupled to each other in a reversible manner so that, after undergoing a surgical training procedure, the second structure (20) can be replaced, in particular independently of the first structure (10).
The present invention relates to a process for the preparation of a biopolymer obtained from the cutin contained in tomato skin and the applications thereof for the production of biomedical devices and products for personal hygiene.
6.
NEW BORON-BASED COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
The present invention relates to new boron-based compounds for the treatment of Alzheimer's disease by irradiation with neutrons amplified by neutron capture reactions (Capture-Enhanced Neutron Irradiation, CENI), and the relative preparation methods.
A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
7.
METHOD FOR THE PRODUCTION OF A SHAPE-MEMORY TISSUE AND RELATIVE USES
The present invention consists of a method for the production of a shape-memory tissue through the use of polymeric matrices capable of temporarily modifying their shape, following the application of an external stimulus, and at the same time capable of supporting the vehiculation of cells and/or drugs.
D01D 5/00 - Formation of filaments, threads, or the like
D01F 6/62 - Monocomponent man-made filaments or the like of synthetic polymersManufacture thereof from homopolycondensation products from polyesters
D01F 6/84 - Monocomponent man-made filaments or the like of synthetic polymersManufacture thereof from copolycondensation products from copolyesters
D01F 6/92 - Monocomponent man-made filaments or the like of synthetic polymersManufacture thereof from mixtures of polycondensation products as major constituent with other polymers or low-molecular-weight compounds of polyesters
8.
NOVEL FORMULATIONS FOR BIOBASED NANOSTRUCTURED FILMS AND COATINGS
The present invention refers to novel compositions based on deacetylated chitin nanowhiskers (CsNWs) as well as to processes for their preparation. Furthermore, the invention relates to a process for preparing films or coatings starting from said compositions as well as to biomedical, cosmetic articles based upon said compositions and uses thereof.
The present invention relates to silk fibroin bioinks specifically formulated for use in 3D bioprinting and the production of ex-vivo models capable of supporting hematopoiesis and the production of platelets and blood cells.
Vascular simulation device (100) for medical training of ultrasound-guided procedures, in particular for realistically simulating ultrasound-guided medical manoeuvres of puncturing blood vessels in an inguinal-femoral region and/or a subclavian/axillary region. The device (100) comprises at least a first vascular structure (40) adapted to let a fluid flow and to simulate an artery, in particular a femoral artery or a subclavian-axillary artery, a second vascular structure (20) adapted to let a fluid flow and to simulate a vein, in particular a femoral vein or a subclavian-axillary vein, and a structure (10), made with a mixture of ballistic gel and graphite or agarose and graphite or silicone and graphite and having echogenic properties, adapted to house at least partially the first vascular structure (40) and the second vascular structure (20). Advantageously, the first vascular structure (40) and/or the second vascular structure (20) are adapted to be fluidically connected to an extracorporeal circulation circuit with circulating liquid (typically a heart-lung machine).
The process for the preparation of low- dimensional perovskite with preferential orientation comprises the phases of: supply of at least a first precursor (A) comprising inorganic iodide; supply of at least a second precursor (B) comprising organic iodide; supply of at least a third precursor (C) selected from at least one of methylammonium iodide and methylammonium chloride; mixing the first precursor (A), the second precursor (B) and the third precursor (C) with at least one solvent selected from the list comprising: N- dimethylformamide (DMF), dimethyl sulfoxide (DMSO), gamma- butyrolactone (GBL) and ethanol (Et-OH) to obtain a precursor mixture; heating of the precursor mixture to a temperature below 100°C; cooling of the precursor mixture; deposition and accretion of the precursor mixture to obtain low-dimensional perovskite with preferential orientation.
H10K 85/50 - Organic perovskitesHybrid organic-inorganic perovskites [HOIP], e.g. CH3NH3PbI3
H10K 30/40 - Organic devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation comprising a p-i-n structure, e.g. having a perovskite absorber between p-type and n-type charge transport layers
12.
PYRIDINE-2-THIOL 1-OXIDE DERIVATIVES AND THEIR USE FOR TREATMENT OF MAMMALIAN INFECTIONS CAUSED BY MYCOBACTERIUM OR FUNGI
The present invention relates to silk fibroin-based scaffolds suitable for supporting the 3D culture of human hematopoietic stem and progenitor cells and/or the production of blood cells ex-vivo, and methods for producing the same.
The present invention relates to covalently cross-linked glycosylated mucin nanoparticles and the use thereof for the delivery and release of active ingredients, markers and/or biomolecules. The subject matter of the invention also relates to covalently cross-linked glycosylated mucin nanoparticles comprising at least one compound selected from an active ingredient, a marker and a biomolecule. The invention further relates to a method for preparing covalently cross-linked glycosylated mucin nanoparticles, optionally comprising at least one compound selected from an active ingredient, a marker and a biomolecule.
The device (100) serves for removing virus particles in an air flow and comprises a tubular member (10) and an envelope (20). The tubular member (10) has an inlet (11) at an end portion and a plurality of outlets (12) at an outer lateral surface and the envelope (20) surrounds totally or partially the tubular member (10). The envelope (20) comprises a gas- permeable and liquid-impermeable membrane and contains virucidal liquid, in particular benzalkonium chloride, more in particular a 5% by weight aqueous solution of benzalkonium chloride. The device is configured so that air enters through the inlet (11), flows in the tubular member (10), escapes through the outlets (12), diffuses in the virucidal liquid, and exits through the gas-permeable and liquid-impermeable membrane of the envelope (20).
A61L 9/14 - Disinfection, sterilisation or deodorisation of air using sprayed or atomised substances
B01D 47/00 - Separating dispersed particles from gases, air or vapours by liquid as separating agent
F24F 8/133 - Treatment, e.g. purification, of air supplied to human living or working spaces otherwise than by heating, cooling, humidifying or drying by separation, e.g. by filtering using wet filtering by direct contact with liquid, e.g. with sprayed liquid
The invention relates to a polymer film obtainable from the crosslinking reaction between pectin and carboxymethylcellulose in the presence of an organic calcium salt and a plasticiser. The film can comprise zeolite, loaded or not loaded with silver ions. The organic calcium salt is selected from: calcium propionate, calcium acetate, calcium lactate, calcium sorbate, calcium glutamate, calcium oleate, calcium palmitate, calcium laurate, calcium stearate and calcium myristate. The plasticising agent is a saturated or unsaturated fatty acid selected from: oleic acid and palmitic, stearic, lauric, myristic, myristoleic, palmitoleic and linoleic acid; polyethylene glycol; glycerol; glycerol derivatives; and citric acid salts, preferably sodium citrate. The polymer film can be laminated to at least one film/layer of plastic material, possibly biodegradable, or to a layer of paper and used for packaging foods, in particular baked products, with the aim of preserving them and extending their shelf life.
B32B 27/28 - Layered products essentially comprising synthetic resin comprising copolymers of synthetic resins not wholly covered by any one of the following subgroups
17.
COMPOSITE COATING MATERIAL, PARTICULARLY FOR SOLAR CELLS
The composite coating material, particularly for solar cells, comprises at least one polymeric matrix and at least one metal-organic framework embedded in the polymeric matrix itself.
UNIVERSITA DEGLI STUDI DI MILANO - BICOCCA (Italy)
Inventor
Collina, Simona
Rossi, Daniela
Linciano, Pasquale
Rossino, Giacomo
Listro, Roberta
Peviani, Marco
Rossi, Silvia Stefania
Vigani, Barbara
Cavaletti, Guido Angelo
Miloso, Mariarosaria
Malacrida, Alessio
Abstract
The present invention is comprised in the field of medicinal chemistry, and it is related to substituted vinyl piperazine-piperidine urea compound which are well effective as antitumoral agents. In particular, they are suitable in methods of treatment of glioblastoma (GB), multiple myeloma (MM) or pancreatic cancer (PC).
A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
The present invention is comprised in the field of medicinal chemistry, and it is related to substituted vinyl piperazine-piperidine urea compound which are well effective as antitumoral agents. In particular, they are suitable in methods of treatment of glioblastoma (GB), multiple myeloma (MM) or pancreatic cancer (PC).
C07D 295/215 - Radicals derived from nitrogen analogues of carbonic acid
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
The present invention consists of a method for the production of a shape-memory tissue through the use of polymeric matrices capable of temporarily modifying their shape, following the application of an external stimulus, and at the same time capable of supporting the vehiculation of cells and/or drugs.
D01D 5/00 - Formation of filaments, threads, or the like
A61L 27/00 - Materials for prostheses or for coating prostheses
C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus
D01F 6/84 - Monocomponent man-made filaments or the like of synthetic polymersManufacture thereof from copolycondensation products from copolyesters
D01F 6/92 - Monocomponent man-made filaments or the like of synthetic polymersManufacture thereof from mixtures of polycondensation products as major constituent with other polymers or low-molecular-weight compounds of polyesters
22.
METHOD FOR THE IDENTIFICATION OF THE WHOLE SEQUENCE OF THE VARIABLE REGION OF THE HEAVY AND LIGHT CHAINS OF IMMUNOGLOBULINS
The present invention relates to a method for the identification of the whole nucleotide sequence of the variable region of the heavy and or light chains of immunoglobulins in a biological sample and the quantification of their relative frequency. The invention is particularly used for the identification of monoclonal heavy and light chains, i.e. tumours, in biological samples from patients suffering from a monoclonal gammapathy.
C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
23.
3D-PATTERNED FIBER MATERIAL FOR THE TOPICAL DELIVERY OF NUCLEIC ACID AND THE PROCESS FOR ITS PREPARATION
C09B 23/08 - Methine or polymethine dyes, e.g. cyanine dyes characterised by the methine chain containing an odd number of CH groups more than three CH groups, e.g. polycarbocyanines
A three-dimensional substrate with structural and compositional gradient for microbial cultures and cocultures is provided. The three-dimensional substrate includes a diffusion system having a first apical compartment placed above a second basolateral compartment, the first and second compartments being separated by a semipermeable membrane, a base solution comprising polysaccharides, proteins and salts or a preformed hydrogel comprising polysaccharides, proteins and salts, and a cross-linking medium comprising salts, culture media and distilled water. A method for preparing a three-dimensional substrate with structural and compositional gradient for microbial cultures and cocultures is also provided.
A process for producing a photosensitive resin for 3D printing includes: (i) treating a vegetable oil with a polyol to form a monoglyceride, (ii) reacting the monoglyceride of step (i) with an unsaturated reagent to form a liquid resin with viscosity lower than 20 Pa·s at the temperature of 20° C., and (iii) mixing the liquid resin with a comonomer and a photoinitiator, as well as the photosensitive resin for 3D printing obtainable from such process and the 3D object obtainable from such photosensitive resin.
B33Y 70/00 - Materials specially adapted for additive manufacturing
C07C 67/08 - Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with the hydroxy or O-metal group of organic compounds
The present invention relates to covalently cross-linked glycosylated mucin nanoparticles and the use thereof for the delivery and release of active ingredients, markers and/or biomolecules. The subject matter of the invention also relates to covalently cross-linked glycosylated mucin nanoparticles comprising at least one compound selected from an active ingredient, a marker and a biomolecule. The invention further relates to a method for preparing covalently cross-linked glycosylated mucin nanoparticles, optionally comprising at least one compound selected from an active ingredient, a marker and a biomolecule.
A61K 31/00 - Medicinal preparations containing organic active ingredients
A61K 47/50 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
The present invention relates to a method for simulating coronary changes and/or for assessing the risk of myocardial ischemia, preferably dynamic stress-induced ischemia.
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
The invention concerns artificial neural networks on quantum computing hardware via a circuit capable of performing neuromorphic operations in a quantum computing environment. It is based on a recent demonstration of a quantum computing version of a single artificial neuron, that performs exponentially better than the classical counterpart when considering the amount of information it can store and elaborate. The present invention combines such neurons via the use of quantum synapses into an artificial (e.g. deep) neural network that will show the same plasticity and ability to undergo machine learning as classical neural networks, while still retaining the exponential advantage coming from the quantum neurons.
The invention concerns an electro-optical modulator, wherein a band-edge slow light in silicon waveguide gratings is applied to Mach- Zehnder modulators based on the plasma dispersion effect. An interleaved p-n junction with the same periodicity as the grating is used, in order to achieve optimal matching between the electromagnetic field profile and the depletion regions of the p-n junction. The resulting modulation efficiency is strongly improved as compared to common modulators based on normal rib waveguides, even in a bandwidth of 20-30 nm near the band edge, while the total insertion loss due to free carriers is not increased. The present invention allows production of slow-light modulators for silicon photonics with reduced energy dissipation.
G02F 1/025 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour based on semiconductor elements having potential barriers, e.g. having a PN or PIN junction in an optical waveguide structure
G02F 1/225 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour by interference in an optical waveguide structure
34.
SYSTEM FOR THE DETERMINATION OF THE SURFACE AND MECHANICAL CHARACTERISTICS OF FILAMENTARY STRUCTURES, IN PARTICULAR SKIN APPENDAGES, STRUCTURES ASSOCIATED THEREWITH, NATURAL OR SYNTHETIC FIBERS AND THEIR AGGREGATES
A system is described for the characterization of vital or reconstituted tissues, in particular skin appendages such as hair or eyelashes or structures associated therewith, comprising in combination: a plurality of sources (12) of electromagnetic radiations adapted to be oriented spatially and to irradiate according to a selected angle of incidence a sample (S) of vital or reconstituted tissue comprising a series of filaments of a person which are homogenous in their structural type; at least one image acquisition device (14) adapted to receive a reflected and/or dispersed radiation from the sample (S), or a fluorescence radiation emitted by the sample (S); and an image processing unit (18) designed to process reflection and/or dispersion images and/or fluorescence images, and to classify the tissue being examined in order to compare the value of at least one out of the parameters of gloss, dimensions, colour intensity, contour of the filaments of the sample (S) with a database of parameters of classes of predetermined vital or reconstituted tissues, and/or to compare the value of at least one out of the parameters of gloss, dimensions, colour intensity, contour of the filaments of the sample (S) with a database of historic values of parameters of the tissue.
The present disclosure provides methods and composition including vaccines, monoclonal antibodies, polyclonal antibodies, chimeric molecule of an extracellular fibrinogen binding protein (Efb) and targeted agent delivery pharmaceutical composition comprising at least a portion of a modified N-terminus region, at least a portion of a modified C-terminus region, or both, wherein the modified extracellular fibrinogen binding protein results in inhibiting the fibrinogen binding, C3 binding, or both or administering to a subject a pharmacologically effective amount of a vaccine in a pharmaceutically acceptable excipient, comprising a modified extracellular fibrinogen binding protein comprising at least a portion of a modified N-terminus region, at least a portion of a modified C-terminus region, or both, wherein the modified extracellular fibrinogen binding protein results in not shielding the staphylococcus bacterium from recognition by a phagocytic receptor.
C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
The present invention relates to a process for preparing nanofibers and nanofiber membranes and to the nanofibers and nanofiber membranes obtainable by such process.
The present invention relates to a three-dimensional substrate with structural and compositional gradient for microbial cultures and cocultures, and to a method for preparing it, where said three-dimensional substrate comprises: - a diffusion system (1) which comprises a first compartment (2) and a second compartment (3), where said first compartment (2) is placed above said second compartment (3), said first and second compartments (2, 3) being separated by a semipermeable membrane (4); - a base solution which comprises polysaccharides, proteins and salts or a preformed hydrogel which comprises polysaccharides, proteins and salts; - a cross-linking medium which comprises salts, culture media and distilled water.
The present invention relates to a three-dimensional substrate with structural and compositional gradient for microbial cultures and cocultures, and to a method for preparing it, where said three-dimensional substrate comprises: - a diffusion system (1) which comprises a first compartment (2) and a second compartment (3), where said first compartment (2) is placed above said second compartment (3), said first and second compartments (2, 3) being separated by a semipermeable membrane (4); - a base solution which comprises polysaccharides, proteins and salts or a preformed hydrogel which comprises polysaccharides, proteins and salts; - a cross-linking medium which comprises salts, culture media and distilled water.
The present invention regards a process for producing a photosensitive resin for 3D printing comprising a step (i) of treating a vegetable oil with a polyol to form a monoglyceride, a step (ii) of reacting the monoglyceride of step (i) with an unsaturated reagent to form a liquid resin with viscosity lower than 20 Pa s at the temperature of 20°C, and a step (iii) of mixing the liquid resin with a comonomer and a photoinitiator, as well as the photosensitive resin for 3D printing obtainable from such process and the 3D object obtainable from such photosensitive resin.
G03F 7/00 - Photomechanical, e.g. photolithographic, production of textured or patterned surfaces, e.g. printed surfacesMaterials therefor, e.g. comprising photoresistsApparatus specially adapted therefor
G03F 7/027 - Non-macromolecular photopolymerisable compounds having carbon-to-carbon double bonds, e.g. ethylenic compounds
G03F 7/029 - Inorganic compoundsOnium compoundsOrganic compounds having hetero atoms other than oxygen, nitrogen or sulfur
G03F 7/031 - Organic compounds not covered by group
G03F 7/038 - Macromolecular compounds which are rendered insoluble or differentially wettable
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Electronic system for detecting the margin between tumour mass in a tissue and healthy tissue, comprising an electronic processing unit (U) which controls a detection probe (2) with an elongated shape and which is traversable. This probe comprises at least one electromagnetic sensor in the microwave frequency range capable of obtaining the dielectric permittivity of the tissue.
Gloeophyllum trabeumCandida, boidinii Pichia pastorisPichia angustaPichia angusta (PaAOX; SEQ ID NO:5), and comprising one or more of the following mutations: (i) the amino acid corresponding to Phe at position 101 of PcAOX is mutated to Gin, Asn, His or Ser; (ii) the amino acid corresponding to Met at position 103 of PcAOX is mutated to Ser, Ala, Gly, Pro or Cys; (iii) the amino acid corresponding to Leu at position 317 of PcAOX is mutated to Val, He, Ala or Met; (iv) the amino acid corresponding to Tyr at position 407 of PcAOX is mutated to Phe, Val, Leu, He or Met; (v) the amino acid corresponding to Trp at position 560 of PcAOX is mutated to Cys, Met, Ala, Val, Leu or Ile.
The present invention generally relates to a MPNs marker and particularly to a biomarker associated with MF. The present invention provides a method for diagnosis, prognosing or staging MPNs, in particular PMF, by measuring a specific marker. Accordingly, a first aspect of the present invention relates to an assay method for the detection and quantification of the levels of EDA FN in a biological sample. Moreover, a second aspect of the present invention relates to a method for diagnosis, prognosing or staging MF in a living subject based on the measured levels of EDA FN.
The present invention relates to a process for preparing nanofibers and nanofiber membranes and to the nanofibers and nanofiber membranes obtainable by such process.
It is disclosed a method for manufacturing a ceramic object, the method comprising the following steps: providing a sample of the object by means of a three-dimensional printing technology, wherein the sample is made from a precursor material comprising a material comprising carbon, and an inorganic component; and submitting the sample to a thermal treatment comprising a process involving the reaction of the carbon with the inorganic component in order to obtain the ceramic object.
C04B 35/56 - Shaped ceramic products characterised by their compositionCeramic compositionsProcessing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on non-oxides based on carbides
B22F 3/105 - Sintering only by using electric current, laser radiation or plasma
C04B 35/573 - Fine ceramics obtained by reaction sintering
C04B 35/65 - Reaction sintering of free metal- or free silicon-containing compositions
B29C 64/124 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using layers of liquid which are selectively solidified
B29C 64/118 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using filamentary material being melted, e.g. fused deposition modelling [FDM]
CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (Spain)
UNIVERSITÀ DEGLI STUDI DI PAVIA (Italy)
UNIVERSITAT JAUME I (Spain)
Inventor
Morales Sánchez, Juan Carlos
Pérez-Victoria Moreno De Barreda, José María
Arévalo Ruíz, Matilde
Belmonte Reche, Efres
Martínez García, Marta
Lucas Rodríguez, Ricardo
López Rubio, José Juan
Freccero, Mauro
Doria, Filippo
Carda Usó, Pedro Miguel
Falomir Ventura, Eva
Abstract
The invention relates to novel compounds which are naphthalene diimide sugar conjugates of general formula (I) and its procedure of obtainment. The compounds of the invention are used in therapy; particularly they have shown antiproliferative, antitrypanosomal and antimalarial activity.
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
It is described a surgical instrument to facilitate the introduction of the internal component of a cochlear implant, CI, comprising two crossed arms connected by a joint, wherein each arm acts as a first class lever and the joint acts as a fulcrum, wherein the tool comprises two rings, one for each arm, configured to accommodate two fingers of the hand of a surgeon, characterized by comprising a retainer for retaining a portion of said inner cochlear implant component, wherein said retainer comprises two movable half-cylinders which are hinged one to each other.
The present invention relates to a mutation of the catalytic domain of a NADPH oxidase (NOX) and the use thereof to facilitate crystal structure determination, and to the corresponding mutated form of NOX and the use thereof to design and produce chemical scaffolds for the generation of NOX ligands effective in different diseases.
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
INSTITUT PASTEUR DE LILLE (France)
UNIVERSITA' DEGLI STUDI DI PAVIA (Italy)
UNIVERSITÉ DE LILLE (France)
Inventor
Vicogne, Jerome
Melnyk, Oleg
Ollivier, Nathalie
Adriaenssens, Eric
Leclercq, Berenice
Simonneau, Claire
De Nola, Giovanni
Gherardi, Ermanno
De Jonge, Hugo
Abstract
Disclosed are proteins derived from the HGF/SF which are able to induce activation of the tyrosine kinase receptor MET and their uses, in particular to promote tissue regeneration. Further disclosed are nucleic acid molecules coding such protein, expression vectors containing such nucleic acid molecule, host cells containing such expression vectors, and related compositions.
It is disclosed an optical transmitter for a network apparatus of a fiber optic communication network. The optical transmitter comprises an optical source in turn comprising an optical cavity and a phase modulator inside the optical cavity. The optical transmitter further comprises an electrical signal generator configured to encode, according to a return-to-zero scheme, a sequence of bits to be transmitted as a multi-level electrical signal for driving the phase modulator to generate a multi-level phase modulated optical signal.
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITA' DEGLI STUDI DI PAVIA (Italy)
INSTITUT PASTEUR DE LILLE (France)
UNIVERSITE DE LILLE (France)
Inventor
Vicogne, Jerome
Melnyk, Oleg
Ollivier, Nathalie
Adriaenssens, Eric
Leclercq, Berenice
Simonneau, Claire
De Nola, Giovanni
Gherardi, Ermanno
De Jonge, Hugo
Abstract
The present invention relates to proteins derived from the HGF/SF which are able to induce activation of the tyrosine kinase receptor MET and their uses, in particular to promote tissue regeneration.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
UNIVERSITE DES SCIENCES ET TECHNOLOGIES DE LILLE-LILLE 1 (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
INSTITUT PASTEUR DE LILLE (France)
UNIVERSITE DE LILLE 2 DROIT ET SANTE (France)
UNIVERSITA' DEGLI STUDI DI PAVIA (Italy)
Inventor
Vicogne, Jerome
Melnyk, Oleg
Ollivier, Nathalie
Adriaenssens, Eric
Leclercq, Berenice
Simonneau, Claire
De Nola, Giovanni
Gherardi, Ermanno
De Jonge, Hugo
Abstract
The present invention relates to multimeric compounds of K1 domains from the Hepatocyte Growth Factor / Scatter Factor (HGF/SF) being able to induce activation of the tyrosine kinase receptor MET and their uses.
A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
G01N 33/74 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving hormones
UNIVERSITE DES SCIENCES ET TECHNOLOGIES DE LILLE-LILLE 1 (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
INSTITUT PASTEUR DE LILLE (France)
UNIVERSITE DE LILLE 2 DROIT ET SANTE (France)
UNIVERSITA' DEGLI STUDI DI PAVIA (Italy)
Inventor
Vicogne, Jerome
Melnyk, Oleg
Ollivier, Nathalie
Adriaenssens, Eric
Leclercq, Berenice
Simonneau, Claire
De Nola, Giovanni
Gherardi, Ermanno
De Jonge, Hugo
Abstract
The present invention relates to proteins derived from the HGF/SF which are able to induce activation of the tyrosine kinase receptor MET and their uses, in particular to promote tissue regeneration.
The present invention relates to an oil-in-water nanoemulsion comprising an oil phase comprising at least one essential oil or water- immiscible phase comprising a hydrophobic polymer and/or a hydrophobic active dispersed in an aqueous phase, said nanoemulsion comprising nanometric droplets of said essential oil or said active with an interface consisting of amphiphilic derivatives of chitosan and at least one fatty acid, obtained by ionic interaction between the deacetylated amino groups of said chitosan and the carboxylic groups of said fatty acid.
The present invention relates to the use of arylalkanolamine compounds with sigma-1 receptor antagonist activity. In particular, the said arylalkanolamine compounds are useful in the treatment of conditions selected from the abuse of psychotropic substances such as cocaine or amphetamines, pain and cancer.
A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 31/4174 - Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
A61K 31/4453 - Non-condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A61K 31/54 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
59.
SYSTEM FOR DETERMINING THE MORPHOLOGICAL CHARACTERISTICS AND MECHANICAL PROPERTIES OF LIVING OR RECONSTITUTED TISSUES, IN PARTICULAR CUTANEOUS APPENDAGES, OR STRUCTURES ASSOCIATED THEREWITH
A system is described for characterizing living or reconstituted tissues, in particular cutaneous appendages such as nails and the like or structures associated therewith, comprising: - a plurality of supports (12a- 12c) for a cutaneous appendage (N) under test, each of which is adapted to form at least one point of support of the cutaneous appendage (N) when this is subjected to application of a predetermined characterizing force; an image acquisition device (20) of the cutaneous appendage (N) under test, adapted to acquire a plurality of successive images over time representative of the geometric configuration of the cutaneous appendage (N); and a processing unit (30) coupled to the image acquisition device (20) and adapted to correlate the acquired images representative of the geometric configuration of the cutaneous appendage (N) with the characterizing forces applied.
SCUOLA UNIVERSITARIA PROFESSIONALE DELLA SVIZZERA ITALIANA (Switzerland)
NEMBRI INDUSTRIE TESSILI S.R.L. (Italy)
INNOVHUB - STAZIONI SPERIMENTALI PER L'INDUSTRIA (Italy)
UNIVERSITA' DEGLI STUDI DI PAVIA (Italy)
CENTRO TESSILE SERICO - SOCIETA' CONSORTILE PER AZIONI (Italy)
Inventor
Iamartino, Piero
Longhi, Renzo
Sorlini, Marzio
Nembri, Giorgio
Farago', Silvio
Torre, Maria Luisa
Gatti, Francesco
Abstract
The present invention relates to spray compositions comprising fibroin and a co-micronised alginic acid salt, a micronised calcium salt and a source of silver and/or copper, and the corresponding manufacturing processes.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 9/00 - Medicinal preparations characterised by special physical form
It is disclosed a two-photon excited fluorescence microscope comprising a laser source suitable for emitting a light beam and an optical arrangement suitable for receiving the light beam from the laser source. The optical arrangement is configured for shaping the light beam so that, at the output of the microscope, the light beam is substantially collimated in a first transverse direction perpendicular to the propagation direction of the light beam at the microscope output and is focused in a second transverse direction perpendicular to the first transverse direction and to the propagation direction, thereby forming a line parallel to the first transverse direction.
Universita Degli Studi di Roma “La Sapienza” (Italy)
Fondazione IEO (Italy)
Universita Degli Studi di Pavia (Italy)
Universita Degli Studi di Milano (Italy)
Inventor
Minucci, Saverio
Mai, Antonello
Mattevi, Andrea
Abstract
3 are as defined in the specification. The invention also relates to the preparation of these compounds, as well as to compositions containing them and to therapeutic use thereof.
UNIVERSITA DEGLI STUDI DI ROMA "LA SAPIENZA" (Italy)
UNIVERSITA' DEGLI STUDI DI PAVIA (Italy)
FONDAZIONE ISTITUTO EUROPEO DI ONCOLOGIA E CENTRO CARDIOLOGICO FONDAZIONE MONZINO (Italy)
Inventor
Minucci, Saverio
Mai, Antonello
Mattevi, Andrea
Abstract
Tranylcypromme derivatives useful as therapeutic agents, particularly for the prevention and/or treatment of diseasesand conditions associated with the activity of histone demethylases LSD1 and LSD2, such as the diseases characterized by deregulation of gene transcription, cell differentiation and proliferation, e g tumors, viral infections, are herem described. These compounds belong to the structural formula (I) wherein A and R3 are as defined in the specification The invention also relates to the preparation of these compounds, as well as to compositions containing them and to therapeutic use thereof.
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/17 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine
A61K 31/325 - Carbamic acidsThiocarbamic acidsAnhydrides or salts thereof
A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
C07C 233/43 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
C07C 233/44 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a carbon atom of an unsaturated carbon skeleton
C07C 233/80 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
C07C 271/22 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
C07C 271/28 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
C07C 275/24 - Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
C07D 333/60 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
64.
TRANYLCYPROMINE DERIVATIVES AS INHIBITORS OF HISTONE DEMETHYLASE LSD1 AND/OR LSD2
UNIVERSITÀ DEGLI STUDI DI ROMA "LA SAPIENZA" (Italy)
FONDAZIONE IEO (Italy)
UNIVERSITÀ DEGLI STUDI DI PAVIA (Italy)
UNIVERSITÀ DEGLI STUDI DI MILANO (Italy)
Inventor
Minucci, Saverio
Mai, Antonello
Mattevi, Andrea
Abstract
Tranylcypromine derivatives useful as therapeutic agents, particularly for the prevention and/or treatment of diseases and conditions associated with the activity of histone demethylases LSD1 and LSD2, such as the diseases characterized by deregulation of gene transcription, cell differentiation and proliferation, e.g. tumors, viral infections, are herein described. These compounds belong to the structural formula (I) wherein A and R3 are as defined in the specification. The invention also relates to the preparation of these compounds, as well as to compositions containing them and to therapeutic use thereof.
C07C 233/43 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
C07C 233/44 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a carbon atom of an unsaturated carbon skeleton
C07C 233/80 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
C07C 271/22 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
C07C 271/28 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
C07C 275/24 - Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
C07D 333/60 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/17 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine
A61K 31/325 - Carbamic acidsThiocarbamic acidsAnhydrides or salts thereof
A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
The present invention concerns a system as well as a method for the evaluation of the vestibular functionality in a subject. The system comprises a display unit for showing a visual target such as an optotype to the patient, a device for measuring rotational acceleration that rotates integrally with the patient's head, and a recording unit. The method of the invention may also be suitably used for the rehabilitation of the peripheral vestibular functionality.
A61B 3/028 - Subjective types, i.e. testing apparatus requiring the active assistance of the patient for testing visual acuitySubjective types, i.e. testing apparatus requiring the active assistance of the patient for determination of refraction, e.g. phoropters
A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
66.
PLATELETS LYSATE AND BIOADESIVE COMPOSITIONS THEREOF FOR THE TREATMENT OF MUCOSITIS
The present invention concerns the use of platelet lysate for treating and/or preventing mucositis. Moreover, a mucoadhesive composition comprising such a platelet lysate for the therapy and/or prevention of mucositis and of corneal lesions is described.
The present invention relates to a screening method for the identification of new benzothiazinone drugs for the treatment of tuberculosis. The method comprises the use of the nitroreductase Nfnb from Mycobacterium smegmatis GM22, which has no mutation compared to other mycobateria nitroreductases.
C12Q 1/26 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving oxidoreductase
G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
The present invention discloses a new L-asparaginase from Helicobacter pylori. The recombinant enzyme cloned from Escherichia coli has been isolated, purified and characterized. It can be used as a new therapeutic and diagnostic tool. Further, its application as a food additive has been disclosed.
is disclosed a device for manipulating a particle immersed in a fluid, comprising a probe having a first end, a second end and a longitudinal axis. The probe receives a radiation from a light source and emits the radiation by means of the second end. The probe comprises: an optical guide structure suitable for receiving the radiation. The optical guide structure is configured so that: at the second end, the radiation has an optical intensity distribution with an intensity maximum placed at a non- zero distance from the longitudinal axis of the probe;and in the region of the intensity maximum, the radiation is reflected at the interface between the second end and the fluid and is emitted by the second end so that it converges in a convergence point, thus creating an equilibrium point. The probe further comprises perturbation optical means for perturbing the equilibrium point.
It is disclosed an optical device for trapping a particle immersed in a fluid. The device of the invention comprises a light source and a probe for guiding and outputting the radiation received from the source. According to the invention, the guided radiation has an intensity distribution having intensity maximum placed at a non-zero distance from the probe longitudinal axis and having rotational symmetry about the longitudinal axis. Further, according to the invention, the intensity maximum is reflected at the interface between probe and fluid, and then it is output by the probe so that it creates a stable equilibrium point wherein the particle is trapped.
Object of the invention is an interactive dressing the treatment of dermatological disorders. The invention comprises: a support, preferably a tissue non-tissue gauze, a hydrogel of a bioadhesive polymer like chitosan or hydroxyethylcellulose and liposomal systems containing an active principle of protein nature. It is a solid therapeutic system consisting of a dispersion of liposomes in hydrogel adsorbed on a tissue non-tissue gauze. The association of hydrogel with liposomal systems allows the site specific and prolonged release of active substances, through intracellular transfer of liposomes and therefore of the encapsulated drug. In addition to act as a storage form, liposomes protect the drug from enzymatic attacks, thus preserving its activity. The therapeutic system containing preferably the prolidase enzyme is used for the treatment, in human and mammals, of dermatological disorders with or without epithelial ulcers, preferably for treatment of ulcers in subjects affected by genetic prolidase deficiency.
A61L 15/38 - Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing enzymes
A61L 15/32 - Proteins, polypeptidesDegradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
A61L 15/20 - Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing organic materials
72.
MICROPARTICULATE SYSTEMS FOR THE ORAL ADMINISTRATION OF BIOLOGICALLY ACTIVE SUBSTANCES
The present invention relates to gastroresistant and enterosoluble microparticulate systems for the encapsulation of biologically active substances selected from: flavonoids, vitamins, antioxidants, immunostimulants, starchy and non-starchy polysaccharides, probiotics, prebiotics, intestinal trophism regulators, oligoelements, enzymes and bioactive peptides. Such microparticulate systems allow the administration of the aforementioned nutraceutic substances to animals such as porcines, bovines, caprines, ovines, equids, canids, felines, camelids, lagomorphs, rodents, fowl, and other mammals, including humans, fish and crustaceans, increasing the bioavailability.
The present invention relates, in general, to devices for optimising image-taking, to optical components comprised in said devices and to a method for optimising image- taking in applications wherein photo-detecting elements with pixel-board processing are provided. The device comprises an objective (110) arranged for focalising the image or optical information on a focal plane (12) and at least one chip (120) of photo-detecting elements with pixel-board processing (112) having photo-sensitive elements (46) and circuit elements (48). The device further comprises at least one optical component (100) having a plurality of concentrators (41) and corresponding optical elements shaped so as to collect the optical information present in the focal plane (12) and concentrate said optical information on the photo-sensitive elements (46).
FONDAZIONE SALVATORE MAUGERI CLINICA DEL LAVORO E DELLA RIABILITAZIONE I.R.C.C.S. (Italy)
UNIVERSITA' DEGLI STUDI DI PAVIA (Italy)
Inventor
Priori, Silvia Giuliana
Abstract
The present invention is based on the identification of new mutations in KCNQ1 (also termed KvLQTI), KCNH2 (also termed HERG), SCN5A, KCNE1 (also termed minK), KCNE2 (also termed MiRP) genes that encode ionic channels involved in cardiac electrical activity and are potentially responsible for the Long QT Syndrome. According to a main aspect, the invention relates to nucleic acids, oligonucleotides and polynucleotides and mRNA, containing sequences of KCNQ1 , KCNH2 SCN5A, KCNE1 , KCNE2 genes and cDNAs in a mutated form and to respective variant proteins thereof. A preferred embodiment of the present invention is represented by a diagnostic method based on the identification of a group of about 70 non-private mutations in the KCNQ1 , KCNH2 and SCN5A genes, detected at high frequency. The method, which is able to identify about 40% of the probands, is non exclusively based on identification of mutations that are described and characterized in this invention where said identification has both prognostic and diagnostic value for the Long QT Syndrome.
